In 1996, a compound with JAK2 inhibitory activity was reported to inhibit acute lymphoblastic leukemia (ALL) cell growth [22]: it was the first evidence of the role of JAKs as druggable targets. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.